AbbVie: The Riskiest Dividend Aristocrat

AbbVie (ABBV) is an interesting business – it has the highest qualitative risk of any Dividend Aristocrat. Risk and Dividend Aristocrats typically do not go together. Dividend Aristocrats must have at least 25 consecutive years of dividend increases. They are typically the ‘bluest of the blue chips’, with names like Wal-Mart (WMT), Coca-Cola (KO), and … Read more

Gilead Sciences (GILD) Stock | Do I Smell Low Cost Opportunity?

Gilead Sciences, Inc (NASDAQ: GILD) When it comes to the biotech sector, Gilead Sciences is one of the most talked about stocks; and for good reason. It’s arguably the most interesting success story in biotech to date! The company has taken full control of both the HIV treatment market and the HCV treatment market; however, … Read more

Gilead Sciences (GILD) Stock Presents A Buying Opportunity

Gilead Sciences, Inc. (NASDAQ: GILD) Gilead Sciences is one of my favorite stocks to follow; and I’d be willing to bet that I’m not the only person that feels that way. With a stronghold on the hepatitis C and HIV markets, Gilead proves to be stronger and stronger with each passing month; and yesterday, the … Read more

Gilead Sciences (GILD) Stock Declines On HCV Sales Issues

Gilead Sciences, Inc. (NASDAQ: GILD) | AbbVie Inc. (NYSE: ABBV) Gilead Sciences has made a major name for itself in the healthcare market; taking the hepatitis C virus and HIV treatment markets by storm. However, AbbVie has recently stepped in to challenge Gilead’s position in the HCV market; and unfortunately we’re seeing a decline in … Read more

Why Gilead Sciences Should Buy Out Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) | Gilead Sciences, Inc. (NASDAQ: GILD) Yesterday, major rumors started to fly around in market talk that Gilead Sciences was planning on acquiring Gilead Sciences. The rumors started because both ACHN and GILD were believed to have missed the UBS conference scheduled yesterday. While some may be pointing to the … Read more

Gilead (GILD) | AbbVie (ABBV) | Breaking Down The HCV Pricing Battle

Gilead Sciences, Inc. (NASDAQ: GILD) AbbVie Inc (NYSE: ABBV) Before I get into the details, this article was written as a request from Ward Agular Financial Inc. If you haven’t checked out their website, it’s well worth doing. Click here to check them out! I’ve been following Gilead Sciences for quite some time now; and I have … Read more

Gilead Sciences (GILD) Won’t Be Giving Up The HCV Throne Any Time Soon

Gilead Sciences, Inc. (NASDAQ: GILD) When we talk about Gilead Sciences, the main topic of discussion is HCV. While the company is the leader in treatments for both HCV and HIV, competition in the HCV market became fierce as AbbVie Inc (NYSE: ABBV). However, even with a price war and added competition, GILD still takes … Read more

Gilead Sciences (GILD) HCV Treatment Added To WHO’s “Essential Medicine” List

Gilead Sciences, Inc. (NASDAQ: GILD) Gilead Sciences has been in the midst of an interesting battle with regard to pricing of it’s HCV treatments Harvoni and Sovaldi. While the treatments have been proven to be incredibly effective, they are also incredibly expensive; limiting access to some patients that could greatly benefit from treatment. As a … Read more